Reig Jofre submits results note on fourth quarter of 2021

REIG JOFRE’s revenues and EBITDA grew by 3% in 2021

REIG JOFRE, in its commitment to society and the pandemic situation, has made a significant effort in 2021 to make the new injectables plant in Barcelona available and adapted to the manufacturing requirements of COVID-19 vaccines in case of future need.

At year-end 2021, listed company REIG JOFRE achieved €236 million in sales, a 3% increase over the same period of the previous year. In 2021 there is a lower consumption of antibiotics and essential products linked to COVID-19, which is offset by growth in prescription and consumer healthcare products, especially at the international level. EBITDA grew by 3%, reaching €27.3 million.

The Pharmaceutical Technologies division, devoted to injectable and antibiotic products, had a decrease in its revenue, while there is already a clear recovery in the Specialty Pharmacare division, focused on prescription medical products, and in Consumer Healthcare, particularly in the FORTE PHARMA brand in French and Benelux markets.

Download the full document (PDF)